Department of Clinical Sciences and Community Health, University of Milan, Endocrinology and Diabetology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Hum Mutat. 2013 Mar;34(3):411-6. doi: 10.1002/humu.22265. Epub 2013 Jan 18.
Pseudohypoparathyroidism (PHP) is a rare heterogeneous genetic disorder characterized by end-organ resistance to parathyroid hormone due to partial deficiency of the α subunit of the stimulatory G protein (Gsα), encoded by the GNAS gene. Heterozygous inactivating GNAS mutations lead to either PHP type Ia (PHP-Ia), when maternally inherited, or pseudo-pseudohypoparathroidism (PPHP), if paternally derived. Both diseases feature typical physical traits identified as Albright's hereditary osteodystrophy in the presence or absence of multihormone resistance, respectively. GNAS mutations are detected in 60-70% of affected subjects, most patients/families harbor private mutations and no genotype-phenotype correlation has been found to date. We investigated Gsα-coding GNAS exons in a large panel of PHP-Ia-PPHP patients collected over the past decade in the two Italian referring centers for PHP. Of 49 patients carrying GNAS mutations, we identified 15 novel mutations in 19 patients. No apparent correlation was found between clinical/biochemical data and results of molecular analysis. Furthermore, we summarized the current knowledge of GNAS molecular pathology and updated the GNAS-locus-specific database. These results further expand the spectrum of GNAS mutations associated with PHP/PPHP and underline the importance of identifying such genetic alterations to supplement clinical evaluation and genetic counseling.
假性甲状旁腺功能减退症(PHP)是一种罕见的异质性遗传疾病,其特征为甲状旁腺激素作用的靶器官(如骨骼和肾脏)对甲状旁腺激素抵抗,这是由于刺激型 G 蛋白(Gsα)的α亚基(由 GNAS 基因编码)部分缺失所致。GNAS 基因的杂合失活突变导致 PHP-Ia(当从母系遗传时)或假性假性甲状旁腺功能减退症(PPHP(当从父系遗传时)。这两种疾病均具有特征性的身体特征,在存在或不存在多激素抵抗的情况下,分别被识别为 Albright 遗传性骨营养不良。在 60-70%的受影响的患者中检测到 GNAS 突变,大多数患者/家系携带私有突变,且迄今为止尚未发现基因型-表型相关性。我们在过去十年中在意大利的两个 PHP 参考中心收集的大量 PHP-Ia-PPHP 患者的 Gsα 编码 GNAS 外显子中进行了研究。在携带 GNAS 突变的 49 名患者中,我们在 19 名患者中发现了 15 种新的突变。临床/生化数据和分子分析结果之间未发现明显相关性。此外,我们总结了 GNAS 分子病理学的最新知识,并更新了 GNAS 基因座特异性数据库。这些结果进一步扩大了与 PHP/PPHP 相关的 GNAS 突变谱,并强调了识别这些遗传改变以补充临床评估和遗传咨询的重要性。